Is FBIO's Q2 2024 EPS growth a sign of recovery?

**Fortress Biotech's (FBIO) Q2 2024 EPS of -$0.73 does not indicate recovery**. Here's why: 1. **Negative EPS**: The fact that the EPS is negative suggests that the company has experienced a loss during the quarter, which is not a sign of recovery. 2. **Consistent Performance**: FBIO's stock has been rated "sell" by StockNews.com and "hold" by Cantor Fitzgerald, with recent sales by a director, indicating a lack of confidence in the stock's short-term performance. This sentiment is not consistent with a recovering stock. 3. **Financial Health Concerns**: The downgrade to "sell" by StockNews.com and the sale of shares by a director at a higher price point than the current trading price suggest that there may be underlying concerns about the company's financial health, which is not indicative of a recovery. 4. **Market Perception**: The market's perception of FBIO remains cautious, as evidenced by the recent downgrades and the company's stock price being lower than the average sale price of the director's recent sale. This indicates that investors may not be anticipating a recovery in the near term. In conclusion, the Q2 2024 EPS of -$0.73, combined with the recent analyst ratings and insider trading activity, does not suggest that Fortress Biotech is on a path to recovery.